carecompany.com.au

Chrisofix AG Ltd products are now available in Australia

Reduce pain and improve healing time

The Chrisofix® Chest Orthosis (rib splint) is an effective and easy-to-use device for the treatment of rib fractures. It quickly reduces pain and increases the forced vital capacity. It decreases the paradoxical thoracic movement, if present, and reduces the risk of late complications. It is easy to apply securely in the correct position on fractured rib site. The orthosis is also comfortable to wear, hypoallergenic and X-ray transparent.

Chrisofix® Chest Orthosis

The ribs enclose vital organs such as the heart and lungs, so chest trauma can cause life-threatening injuries and reduce the respiratory area, causing restrictive breathing difficulties with serious consequences.

The principle of the Chrisofix® Chest Orthosis is to immobilise the affected area. The splint works because it is very stable due to its patented thin corrugated aluminium core covered with non-allergenic polyethylene foil. It is also breathable due to a cotton laminated polyethylene coat with perforations.

- Faster pain reduction
- Less painkiller needed
- Accelerated recovery of respiratory function
- Shorter hospitalisation
- Reduced risk of pneumonia
- Transparent to X-rays
- Patient can take a shower with it

MEASUREMENT		REF. NUMBER
S (small)	17 × 12 cm	604 226 104
L (large)	17 × 17 cm	608 226 104

Act now! Call 1800 28 44 46

Chrisofix's unique products

The technology and product ranges for pre-hospital, hospital and therapy use have been developed by Dr Kalman Bolla, founder of Chrisofix® AG Ltd Switzerland.

Since 1995, Chrisofix® AG Ltd has been continuously extending its product range by developing new, patent-protected technologies and products, manufactured to meet ISO 13485:2016 standards.

Clinical study references

L. Zsiros, Z. Záborszky, et al. Easy and effective method for the treatment of rib fracture by using Chrisofix® technique. 7th European Trauma Congress, Ljubljana, 2006.

A non-randomised, placebo-controlled single-blind multicenter study on 106 hospitalised patients: the Chrisofix® treated group of patients was in all assessments older and had more fractured ribs. The results are presented in the graphics to the right.

This report includes clinical studies (a randomised and a subsequently evaluated clinical study) which were evaluated and subjected to a meta-analysis. The cause of hospitalisation of the patients was for 2–7 rib fractures. In the two studies 14 and 26 patients respectively were treated with the splint while 16 patients comprised the control groups in each of the two studies. The splinted patients were hospitalised for on average 2.2 days less than the control group.

T. Mészáros, A. Sárváry et al. Use of Chest Orthosis can significantly shorten the hospitalisation of rib fracture patients. 7th European Trauma Congress, Ljubljana, 2006.



The pain becomes significantly (p<0,05) reduced immediately after the splint application to the patient.



Changes (mL) in the forced vital capacity (FVC) after admission and splint application (p<0,01).

MEASUREMENT		REF. NUMBER
S (small)	17 × 12 cm	604 226 104
L (large)	17 × 17 cm	608 226 104

REGISTERED ISO 13485

ndis National Disability Insurance Scheme
Registered provider